Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03999164 · ClinicalTrials.gov registry record · Phase 1
Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy
A Phase 1 study of Epilepsy, Post-Traumatic, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03999164: Recruiting Phase 1 study of Epilepsy, Post-Traumatic, sponsored by University of California, Davis.
NCT03999164 is a Phase 1 study of Epilepsy, Post-Traumatic that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03999164, a Phase 1 study of Epilepsy, Post-Traumatic, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to evaluate the time course of inflammation in the brain after a moderate to severe traumatic brain injury using positron emission tomography (PET) brain imaging. Patients will undergo PET scans of the brain at two weeks and two months after injury to measure neuro-inflammation. The results of the PET scans will be analyzed and correlated with the risk of post-traumatic epilepsy.
Conditions Studied
Interventions
- DRUG [18F]DPA-714 Positron Emission Tomography Scan
Study Locations (1)
California
- University of California, Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2026-08-14 |
| Phase | Phase 1 |
What NCT03999164 shows while recruiting
NCT03999164 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Epilepsy, Post-Traumatic appearing as the primary indexed condition, and to 1 intervention - of which [18F]DPA-714 Positron Emission Tomography Scan is the first listed.
NCT03999164 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03999164 about?
NCT03999164 is a clinical study titled "Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy". This study plans to evaluate the time course of inflammation in the brain after a moderate to severe traumatic brain injury using positron emission tomography (PET) brain imaging. Patients will undergo PET scans of the brain at two weeks and two months after injury to measure neuro-inflammation. The...
What is the current status of trial NCT03999164?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-02-01. Estimated completion is 2026-08-14.
What conditions does trial NCT03999164 study?
This clinical trial studies the following conditions: Epilepsy, Post-Traumatic.
What interventions are being tested in trial NCT03999164?
The interventions under investigation include: [18F]DPA-714 Positron Emission Tomography Scan (DRUG).
Who is sponsoring clinical trial NCT03999164?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03999164 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Post-Traumatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03999164's enrollment target sits among peer trials
30 1333rd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI